DCIS

From WikiMD's WELLNESSPEDIA

DCIS or Ductal Carcinoma In Situ is a type of breast cancer that originates in the milk ducts and has not spread to nearby tissue. It is considered the earliest form of breast cancer and is non-invasive.

Overview[edit]

DCIS is characterized by the presence of abnormal cells inside a milk duct in the breast. While DCIS is not life-threatening, it does require treatment to prevent the condition from becoming invasive.

Symptoms[edit]

In most cases, DCIS has no noticeable symptoms. However, it can sometimes cause signs such as a breast lump or bloody nipple discharge. It is usually detected during a mammogram.

Causes[edit]

The exact cause of DCIS is unknown. It is believed to occur when some of the cells lining the milk ducts of the breast start to behave abnormally, multiplying rapidly.

Risk Factors[edit]

Factors that can increase the risk of DCIS include age, a family history of breast cancer, high estrogen levels, and previous radiation therapy to the chest area.

Diagnosis[edit]

DCIS is most commonly detected during a routine mammogram. If an abnormal area is detected, a biopsy may be performed to confirm the diagnosis.

Treatment[edit]

Treatment options for DCIS include surgery (either a lumpectomy or mastectomy), radiation therapy, and hormone therapy. The choice of treatment depends on the size and location of the DCIS, the patient's age and health, and the patient's personal preferences.

Prognosis[edit]

The prognosis for DCIS is generally very good. Most women with DCIS are effectively treated and do not develop invasive breast cancer.

See Also[edit]



Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.